The Yale School of Medicine is the graduate medical school at Yale University in New Haven, Connecticut. It was founded in 1810 as the Medical Institution of Yale College and formally opened in 1813. The primary teaching hospital for the school is Yale New Haven Hospital.

During the past decade, Yale University School of Medicine conducted 385 clinical trials. In the 10-year time frame, 385 clinical trials started and 238 clinical trials were completed, i.e. on average, 61.8% percent of trials that started reached the finish line to date. In the past 5 years, 169 clinical trials started and 125 clinical trials were completed. i.e. 74% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Yale University School of Medicine" #1 sponsor was "Yale University" with 169 trials, followed by "Bristol-Myers Squibb" with 45 trials sponsored, "National Institute of Allergy and Infectious Diseases (NIAID)" with 22 trials sponsored, "Eli Lilly and Company" with 20 trials sponsored and "Hoffmann-La Roche" with 20 trials sponsored. Other sponsors include 439 different institutions and companies that sponsored additional 250 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Yale University School of Medicine" #1 collaborator was "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)" with 32 trials as a collaborator, "National Institute on Drug Abuse (NIDA)" with 25 trials as a collaborator, "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)" with 17 trials as a collaborator, "Yale University" with 17 trials as a collaborator and "National Institute on Aging (NIA)" with 16 trials as a collaborator. Other collaborators include 429 different institutions and companies that were collaborators in the rest 241 trials.

According to Clinical.Site data, the most researched conditions in "Yale University School of Medicine" are "HIV Infections" (26 trials), "Alzheimer's Disease" (22 trials), "Type 1 Diabetes" (21 trials), "Obesity" (15 trials) and "Alzheimer Disease" (14 trials). Many other conditions were trialed in "Yale University School of Medicine" in a lesser frequency.

Most popular intervention types in "Yale University School of Medicine" are "Drug" (454 trials), "Other" (98 trials), "Device" (85 trials), "Biological" (59 trials) and "Behavioral" (52 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (153 trials), "placebo" (17 trials), "Nivolumab" (10 trials), "Atezolizumab" (9 trials) and "Ipilimumab" (8 trials). Other intervention names were less common.

The vast majority of trials in "Yale University School of Medicine" are 655 trials for "All" genders, 47 trials for "Female" genders and 15 trials for "Male" genders.

Currently, there are 188 active trials in "Yale University School of Medicine". 3 are not yet recruiting, 93 are recruiting, 86 are Active, not recruiting, and 6 are Enrolling by invitation. In total, there were 425 completed trials in Yale University School of Medicine, 4 suspended trials, and 85 terminated clinical trials to date.

Out of the total trials that were conducted in Yale University School of Medicine, 89 "Phase 1" clinical trials were conducted, 224 "Phase 2" clinical trials and 197 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 27 trials, and there were also 138 trials that are defined as “Not Applicable".